hrp0086p1-p459 | Fat Metabolism and Obesity P1 | ESPE2016

Erythropoietin Activates Classical Brown Adipose Tissue Through the Erythropoietin Receptor/STAT3 Pathway, Improving Obesity and Glucose Homeostasis in High Fat Diet-induced Obese Mice

Kodo Kazuki , Nakajima Hisakazu , Sugimoto Satoru , Itoh Ikuyo , Syota Fukuhara , Shigehara Keiichi , Nishikawa Taichiro , Mori Jun , Kosaka Kitaro , Hosoi Hajime

Background, aims and objectives: We hypothesized that classical brown adipose tissue (cBAT) could play a crucial role in the anti-obesity effects of erythropoietin (EPO). Our study highlights the mechanism in which EPO treatments could upregulate energy expenditure and improve glucose homeostasis through cBAT in obese mice fed with a high-fat diet (HFD).Method: C57BL/6J mice had been fed with HFD since the age of 4 weeks (HFD mice). We administered recom...

hrp0086p1-p443 | Fat Metabolism and Obesity P1 | ESPE2016

The Collapse of the BDNF/POMC System in the Hypothalamus is Responsible for the Extreme Obesity with Hyperphagia Observed in Female Heterozygous MeCP2 Null Mice

Fukuhara Shota , Nakajima Hisakazu , Kodo Kazuki , Itoh Ikuyo , Shigehara Keiichi , Moroto Masaharu , Sugimoto Satoru , Mori Jun , Kosaka Kitaro , Morimoto Masafumi , Hosoi Hajime

Objective and hypotheses: The aim was to elucidate the mechanism underlying the extreme obesity observed in female heterozygous MeCP2 null mice fed a high-fat diet.Method: We examined the molecular biology and physiology of female heterozygous MeCP2 null mice (Mecp2tm1.1Bird/J, MeCP2+/− mice) fed a high-fat diet (HFD) for 12 weeks since 4 weeks of age using analytical tools. C57/BL6 mice were used as controls.<p class="abs...

hrp0095rfc7.2 | Growth and Syndromes | ESPE2022

Once-Weekly Somapacitan vs Daily GH in Children with GH Deficiency: The Randomized Phase 3 REAL 4 Trial

Miller Bradley , Blair Joanne , Højby Michael , Böttcher Volker , Juul Kildemoes Rasmus , Maniatis Aristides , Beck Bang Rikke , Mori Jun , Polak Michel , Stagi Stefano , Horikawa Reiko

Background: Growth hormone (GH) replacement therapy usually requires daily subcutaneous (s.c.) injections that can be burdensome for patients and their caregivers. Long-acting GH formulations aim to establish a less burdensome dosing regimen that is as safe and efficacious as daily GH to potentially improve adherence and clinical outcomes. Somapacitan, a long-acting reversible albumin-binding GH derivative, is in development for once-weekly s.c. administration...